Thrombophilia and adverse pregnancy outcome.
This article focuses on the clinical evaluation and management of women who have thrombophilia-related placental vascular complications, including fetal loss, pre-eclampsia, intrauterine fetal growth restriction, and placental abruption. All are major causes of maternal and fetal adverse outcomes.
Thrombosis and Hemostasis Unit, Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, PO Box 9602, Haifa 31096, Israel. b_brenner@rambam.health.gov.il
Benjamin
B
Brenner
Anat
A
Aharon
D000037:Abruptio Placentae / Q000503:physiopathology; D005260:Female; D005313:Fetal Death / Q000503:physiopathology; D005317:Fetal Growth Retardation / Q000503:physiopathology; D006487:Hemostasis / Q000502:physiology; D006801:Humans; D020138:Hyperhomocysteinemia / Q000235:genetics / Q000503:physiopathology; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics; D011225:Pre-Eclampsia / Q000503:physiopathology; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000503:physiopathology*; D012307:Risk Factors; D019851:Thrombophilia / Q000503:physiopathology*
D042965:Methylenetetrahydrofolate Reductase (NADPH2)